The European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary

Abstract

Background This article summarizes the ERA-EDTA Registry’s 2016 Annual Report, by describing the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2016 within 36 countries. Methods In 2017 and 2018, the ERA-EDTA Registry received data on patients undergoing RRT for ESRD in 2016 from 52 national or regional renal registries. In all, 32 registries provided individual patient data and 20 provided aggregated data. The incidence and prevalence of RRT and the survival probabilities of these patients were determined. Results In 2016, the incidence of RRT for ESRD was 121 per million population (pmp), ranging from 29 pmp in Ukraine to 251 pmp in Greece. Almost two-thirds of patients were men, over half were aged ≥65 years and almost a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 84% of patients. On 31 December 2016, the prevalence of RRT was 823 pmp, ranging from 188 pmp in Ukraine to 1906 pmp in Portugal. In 2016, the transplant rate was 32 pmp, varying from 3 pmp in Ukraine to 94 pmp in the Spanish region of Catalonia. For patients commencing RRT during 2007–11, the 5-year unadjusted patient survival probability on all RRT modalities combined was 50.5%. For 2016, the incidence and prevalence of RRT were higher among men (187 and 1381 pmp) than women (101 and 827 pmp), and men had a higher rate of kidney transplantation (59 pmp) compared with women (33 pmp). For patients starting dialysis and for patients receiving a kidney transplant during 2007–11, the adjusted patient survival probabilities appeared to be higher for women than for men.

Global Dialysis Perspective: Israel

“…The prevalence of 75-84-year-old patients on dialysis rose 4.8-fold between 1990 and 2015, and currently this is the most frequent age group on dialysis in Israel, comprising 4871 pmp, the highest rate in the ERA-EDTA registry. The prevalence of all types of RRT is 1199 pmp (62% dialysis, 38% transplants) compared to 823 pmp reported as average by the ERA-EDTA and 2096 in the USA (3,4). The prevalence of dialysis in Israel was 742 pmp in 2018 (768 pmp in 2015) (…”

“…In addition to the high rates of DM as primary renal disease and of elderly patients on HD, a unique feature of ESKD in Israel is the recent dramatic rise in altruistic kidney donations (12). Whereas the overall transplant rate in Israel is 43 pmp (compared to averages of 32 pmp European (3) and 62 pmp in the USA (4)), Israel is one of the few countries reporting a substantially higher living donor rate than cadaver transplantation (12) (60% living versus 40% deceased donors, compare with the US with 28% living versus 72% deceased donors). Furthermore, among the living donors, there is a disproportionately high percentage of altruistic donors (54% altruistic versus 46% living-related donors) (12).…”

Development of Bullous Pemphigoid after Tenckhoff Catheter Placement in a Peritoneal Dialysis Patient

“…Patients with end-stage renal disease requiring dialysis show a high prevalence of diabetes mellitus [4]. Due to the risk of drug accumulation and therefore of severe hypoglycaemic episodes, the use of many oral hypoglycaemic drugs, like metformin and sulphonylureas, is precluded.…”

ABO-incompatible living donor kidney transplantation in Portugal

“…Especially in countries with long waiting lists for patients on maintenance dialysis, ABOi kidney transplantation constitutes an attractive alternative therapeutic option. 1,11 During the last decade, the expansion of new, safe and potent immunosuppressors have enabled us to perform ABOi kidney transplantation in many centers worldwide. 11 Patient survival was 100% in the current study.…”

“…Kidney transplantation is the treatment modality of chronic kidney disease G5D of Kidney Disease Improving Global Outcomes most associated with better survival rate and quality of life. 1 The mean time on the waiting list for an available organ in Portugal is about five years and is growing every year. Given the shortage of deceased donors, efforts have been made to expand the living donor pool.…”